Syndax Pharmaceuticals (SNDX) Misses Q3 EPS by 13c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street rallies after Democrats win Congress; data center stocks slide
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts SNDX Hot Sheet
Join SI Premium – FREE
Syndax Pharmaceuticals (NASDAQ: SNDX) reported Q3 EPS of ($0.84), $0.13 worse than the analyst estimate of ($0.71). Revenue for the quarter came in at $305 thousand versus the consensus estimate of $100 thousand.
For earnings history and earnings-related data on Syndax Pharmaceuticals (SNDX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Syndax to present 19 abstracts on two drugs at ASH 2026 meeting
- Uber Q3 profit, revenue beat estimates as gross bookings jump 20%
- Citadel sees year-end stock rally as Wall Street’s biggest buyers return
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
